SMARCB1 and cancer: SMARCB1 deficiency occurs in up to 20% of human cancers [14, 34]; although the majority of SMARCB1 deficient tumors harbor homozygous loss of SMARCB1, numerous papers have reported a subset of these tumors exhibiting heterozygous deletions or extended 22q losses [35, 36, 37].